Participated · Series A · Jun 2026

Dioseve is developing ReproNest (development code DIOS-101), a co-culture IVM product that uses ovarian support cell-like cells differentiated from iPS cells to support maturation of immature oocytes. The co-culture approach cultivates patient-derived oocytes together with support cells in the same system and is not intended as a cell therapy for administration into the body. Non-clinical studies reported by the company have shown potential benefits in supporting oocyte maturation compared with conventional IVM culture conditions. The company's technological strength is its proprietary differentiation induction technology, which it says enables efficient induction of oocytes and ovarian somatic cells from iPS cells and production of ovarian support cell-like cells. Dioseve sees applications in fertility preservation (including oocyte freezing), treatment of patients at high risk of OHSS, and rapid fertility preservation before cancer treatment. The recent funding will support validation, manufacturing and quality control setup, reproducibility assessment, regulatory compliance work, and business development to advance ReproNest toward practical application.

Participated · Series A · May 2026

Kanvas Biosciences develops a spatial biology platform for microbiome drug screening, discovery and manufacturing aimed at accelerating live biotherapeutics development. The company’s lead program is KAN-001, an immuno-oncology candidate for which the recent Series A will fund clinical trials. Kanvas intends to use proceeds to advance commercial partnerships alongside clinical development. Its core technology was initially developed at Cornell University and is exclusively licensed. The company is led by CEO Matthew Cheng. The articles do not report revenue, user metrics, founding year, or prior financing details.

Participated · Series B · Dec 2025

pH7 Technologies operates a commercial PGM extraction facility in Vancouver and is scaling its mining-sector applications beginning with copper. Its proprietary closed-loop organo-electrochemical process is designed to recover metals from low-grade sulfide ore, tailings, and complex feedstocks that have been historically uneconomic or challenging to process. The company’s proposed copper production approach aims to convert low-grade sulfide ore directly into 99.9% pure copper cathodes on-site while generating green hydrogen as a by-product. pH7 says the process could increase recovery from low-grade resources, extend the value of existing mining assets, and strengthen domestic critical mineral supply chains. Current plans include engineering and technology development phases to produce technical and economic data to support future demonstration and commercial deployment across the Canadian mining sector.

Led · Series B · Oct 2025

Seattle-based Membrion, led by CEO and founder Greg Newbloom, provides adaptive water-infrastructure solutions built around its proprietary ceramic desalination membranes. The technology is designed to process the toughest industrial waste streams, allowing manufacturers to reclaim usable water and valuable minerals while meeting evolving environmental regulations and climate-driven pressures. Membrion positions its membranes as a reliability tool for future-proofing production facilities against regulatory shifts and supply-chain risks. With the fresh capital, the company plans to scale operations and accelerate product development. Since inception, Membrion has raised a cumulative $43 million. No revenue or customer counts were disclosed in the article, but the company emphasizes industrial adoption and continued R&D as key growth drivers.

Participated · Series A · Apr 2025

ChEmpower develops abrasive-free polish pads and chemically reactive chemistry for planarization, offering an alternative to traditional CMP that aims to produce defect-free surfaces and improve chip yields. Its core product set includes polishing pads and chemical solutions designed to create superior planarity without abrasives, demonstrated on an abrasive-free 300mm copper technology. The company has established a pilot line for pad production and announced strategic partnerships with leading semiconductor companies. ChEmpower plans to scale its manufacturing systems, commercialize its product offerings, and recruit engineering, business development, and operations talent to expand market reach. The firm emphasizes sustainability by recovering water used in planarization, addressing an industry issue where up to 40% of fab water usage is tied to the planarization process. ChEmpower raised $18.7M in a Series A to accelerate operations and deployment of its technology across fabs worldwide.